Cardiovascular Protection: Major clinical trials like the LEADER trial for liraglutide have shown that GLP-1 RAs can significantly reduce the risk of major adverse cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes
12 mg per week The maximum dose studied, associated with the most pronounced reductions in body weight, with some participants experiencing losses exceeding 24% over a 48-week period
This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment
Common side effects include nausea, diarrhea, vomiting, constipation, stomach discomfort, rash or pain around the injection site, fatigue, burping, hair loss, and gastroesophageal reflux disease
However, in severe cases of dehydration, expert-guided oral intravenous rehydration solutions may be needed 5
The glucagon receptor component adds metabolic effects beyond appetite suppression, including enhanced fat oxidation and energy expenditure
